Quick Answer
Lineage Cell Therapeutics, Inc. reported Stockholders Equity of $44.55 million for fiscal year 2025.
Lineage Cell Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $44.55M | -43.2% |
| 2024 | $78.38M | +23.6% |
| 2023 | $63.42M | -13.5% |
| 2022 | $73.34M | -20.5% |
| 2021 | $92.22M | -4.1% |
| 2020 | $96.20M | -14.8% |
| 2019 | $112.96M | +20.4% |
| 2018 | $93.84M | -42.3% |
| 2017 | $162.64M | +37.9% |
| 2016 | $117.93M | +356.8% |
| 2015 | $25.82M | -29.2% |
| 2014 | $36.46M | +146.3% |
| 2013 | $14.80M | +54.4% |
| 2012 | $9.58M | -66.5% |
| 2011 | $28.65M | -25.0% |
| 2010 | $38.17M | +245.5% |
| 2009 | $11.05M | +354.1% |
| 2008 | -$4.35M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.04M | -66.7% | -54.4% |
| June 30, 2025 | $48.38M | -29.2% | -38.8% |
| March 31, 2025 | $79.03M | +9.2% | +0.8% |
| December 31, 2024 | $78.38M | +23.6% | +18.4% |
| September 30, 2024 | $66.19M | -2.8% | -3.1% |
| June 30, 2024 | $68.30M | -6.0% | -5.7% |
| March 31, 2024 | $72.40M | +2.8% | +14.2% |
| December 31, 2023 | $63.42M | -13.5% | -6.9% |
- Lineage Cell Therapeutics, Inc. showed a decrease of -43.2% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, Lineage Cell Therapeutics, Inc.’s stockholders equity has grown by 1124.9% (from -$4.35 million to $44.55 million).
- The most recent figure is from Lineage Cell Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: